Business Description
Shuttle Pharmaceuticals Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US8256934014
Total Employee Number:
9Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.09 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 57.5 | |||||
3-Year EPS without NRI Growth Rate | 56.5 | |||||
3-Year FCF Growth Rate | 47.7 | |||||
3-Year Book Growth Rate | -78.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.39 | |||||
9-Day RSI | 43.28 | |||||
14-Day RSI | 39.81 | |||||
3-1 Month Momentum % | -31.86 | |||||
6-1 Month Momentum % | -68.66 | |||||
12-1 Month Momentum % | -82.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.3 | |||||
Quick Ratio | 0.3 | |||||
Cash Ratio | 0.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -206.7 | |||||
Shareholder Yield % | -290.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -389.63 | |||||
ROA % | -147.64 | |||||
ROIC % | -212.5 | |||||
3-Year ROIIC % | -85.28 | |||||
ROC (Joel Greenblatt) % | -5316.52 | |||||
ROCE % | -360.04 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.66 | |||||
EV-to-EBIT | -0.14 | |||||
EV-to-EBITDA | -0.15 | |||||
EV-to-FCF | -0.15 | |||||
Earnings Yield (Greenblatt) % | -714.29 | |||||
FCF Yield % | -403.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SHPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shuttle Pharmaceuticals Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -60.622 | ||
| Beta | 1.6609 | ||
| 3-Year Sharpe Ratio | -1.68 | ||
| 3-Year Sortino Ratio | -1.73 | ||
| Volatility % | 111.7 | ||
| 14-Day RSI | 39.81 | ||
| 14-Day ATR ($) | 0.826655 | ||
| 20-Day SMA ($) | 4.36565 | ||
| 12-1 Month Momentum % | -82.61 | ||
| 52-Week Range ($) | 3.1601 - 55.9 | ||
| Shares Outstanding (Mil) | 0.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shuttle Pharmaceuticals Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shuttle Pharmaceuticals Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 46 days | ||
| 0.1:1 Stock Split | 2026-06-11 | 4.89 (+18.40%) | ||
| General meeting for 2026 | 2026-05-21 12:00 | 5.93 (+0.56%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 6.40 (-4.62%) | ||
| Annual report for 2025 | 2026-03-31 | 5.35 (-17.18%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 25.10 (-2.71%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 35.90 (+4.36%) | ||
| 0.04:1 Stock Split | 2025-06-16 | 33.20 (-8.48%) | ||
| General meeting for 2025 | 2025-05-09 12:00 | 67.50 (+3.05%) |
Show
Entries
Shuttle Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Shuttle Pharmaceuticals Holdings Inc(SHPH)'s stock price today?
The current price of SHPH is $3.98. The 52 week high of SHPH is $55.90 and 52 week low is $3.16.
When is next earnings date of Shuttle Pharmaceuticals Holdings Inc(SHPH)?
The next earnings date of Shuttle Pharmaceuticals Holdings Inc(SHPH) is 2026-08-13 Est..
Does Shuttle Pharmaceuticals Holdings Inc(SHPH) pay dividends? If so, how much?
Shuttle Pharmaceuticals Holdings Inc(SHPH) does not pay dividend.
Guru Commentaries on NAS:SHPH
No articles.
Press Release
Articles on Shuttle Pharmaceuticals Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers